Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 877-882

  Ingle, James N ^a   Tu, D ^b   Pater, J L ^b   Muss, H B ^c   Martino, S ^d   Robert, N J ^e   Piccart, M J ^f   Castiglione, M ^g   Shepherd, L E ^b   Pritchard, K I ^h   Livingston, R B ⁱ   Davidson, N E ^j   Norton, L ^k   Perez, E A ^l   Abrams, J S ^m   Cameron, D A ⁿ   Palmer, M J ^b   Goss, P E ^o  

^a MAYO CLINIC   (United States)

^b Queen's Cancer Research Institute   (Canada)

^c UNIVERSITY OF VERMONT   (United States)

^d Angeles Clinic and Research Institute   (United States)

^e INOVA FAIRFAX HOSPITAL   (United States)

^f JULES BORDET INSTITUTE   (Belgium)

^g International Breast Cancer Study Group Coordinating Center   (Switzerland)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l MAYO CLINIC   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF LEEDS   (United Kingdom)

^o MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Extended adjuvant therapy; Intent to treat; Letrozole

Indexed keywords

LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 43049139182     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm566     Document Type: Article

References (11)

1. P.E. Goss J.N. Ingle S. Martino A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 2003 1793 1802
2. P.E. Goss J.N. Ingle S. Martino Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 2005 1262 1271
3. B. Moy D. Tu J.L. Pater Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer Ann Oncol 17 2006 1637 1643
4. J.N. Ingle D.S. Tu J.L. Pater Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial Breast Cancer Res Treat 99 2006 295 300
5. P.E. Goss J.N. Ingle S. Martino National Cancer Institute of Canada Clinical Trials Group MA.17: efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor J Clin Oncol 25 2007 2006 2013
6. K.M. Wasan P.E. Goss P.H. Pritchard The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) Ann Oncol 16 2005 707 715
7. T.J. Whelan P.E. Goss J.N. Ingle Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women J Clin Oncol 23 2005 6931 11640
8. E.A. Perez R.G. Jesse K.I. Pritchard Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 J Clin Oncol 24 2006 3629 3635
9. R. Jakesz H. Samonigg R. Greil Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a) J Clin Oncol 23 2005 10s (Abstr 527)
10. E. Mamounas J.H. Jeong L. Wickerham Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33 Breast Cancer Res Treat 100 Suppl 1 2006 S22 (Abstr 49)
11. P.E. Goss J.N. Ingle J.L. Pater Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer completing 5 years of tamoxifen J Clin Oncol 2007 In press